10-Q: ADIA Nutrition Reports Q2 2026 Results, Faces Going Concern Doubt

ADIA Nutrition, Inc. filed its Q2 2026 10-Q, showing increased revenue but also a net loss and substantial doubt regarding its ability to continue as a going concern.

Summary

• ADIA Nutrition, Inc. filed its quarterly report for the period ending June 30, 2026.
• The company reported total revenue of $661,660 for the first six months of 2026, a significant increase from $189,910 in the same period of 2025.
• Despite revenue growth, the company incurred a net loss of $122,107 for the first six months of 2026, compared to a net loss of $240,216 in the prior year.
• The company has an accumulated deficit of $16,095,589 as of June 30, 2026.
• Management has expressed substantial doubt about the company's ability to continue as a going concern, dependent on generating greater revenues and obtaining capital from third parties.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as having a negative sentiment due to the continued net losses, significant accumulated deficit, and the explicit statement of substantial doubt about the company's ability to continue as a going concern, despite some revenue growth.

Positives

• Total revenue increased to $661,660 for the first six months of 2026, up from $189,910 in the same period of 2025.
• Gross profit improved to $350,157 for the first six months of 2026, compared to $39,975 in the prior year.
• The company generated a net income of $40,418 for the three months ended June 30, 2026, indicating a positive trend within the quarter.
• Revenue from Medical Procedures significantly increased to $434,670 for the first six months of 2026 from $96,700 in the prior year.
• Sales of biologics also saw a substantial increase to $221,525 for the first six months of 2026 from $87,500 in the prior year.

Negatives

• The company incurred a net loss of $122,107 for the six months ended June 30, 2026.
• An accumulated deficit of $16,095,589 exists as of June 30, 2026.
• Substantial doubt is raised about the company's ability to continue as a going concern.
• Total operating expenses increased to $450,248 for the six months ended June 30, 2026, from $267,105 in the prior year.
• The company has a significant line of credit balance of $835,312 outstanding as of June 30, 2026.

Risks

• The company's continuation as a going concern is dependent on its ability to generate greater revenues and obtain capital from third parties.
• There is substantial doubt about the company's ability to continue as a going concern for a reasonable period of time.
• The company may be required to obtain capital from third parties if it cannot cover expenses with its gross profit.
• Forward-looking statements are subject to risks, uncertainties, and other factors outside of the company's control.

Future Outlook

Management anticipates continued growth in revenue and plans to utilize its line of credit facility and identify adequate sources of funding for bridge capital, financing of receivables, and operating capital. The company expects to incur approximately $100,000 in Exchange Act filing costs and $450,000 to $750,000 in operating costs over the next twelve months. Cost of revenue is projected to be 35% to 45% of revenue.

Management Comments

• ADIA is dedicated to revolutionizing healthcare through innovative partnerships, focusing on AHSCT treatments for MS patients and advocating for their inclusion and reimbursement by health insurance companies.
• ADIA envisions a future where AHSCT is a widely accessible and transformative treatment option for MS patients.
• ADIA is committed to revolutionizing the supplement industry through strategic acquisitions and investments in companies that uphold the highest standards of integrity and quality.
• Management anticipates continued growth in revenue and plans to utilize the funding resources it has available (i.e., its line of credit facility) as well as the continued identification of adequate sources of funding to provide bridge capital, financing of receivables, and operating capital for continued growth.

Industry Context

StockSavvy.ai notes that ADIA Nutrition operates in the health and wellness sector, with a dual focus on medical procedures (specifically AHSCT for MS) and supplement sales. The company's strategy involves partnerships with healthcare providers and insurers for its medical treatments, and strategic acquisitions for its supplement business. The increasing revenue in medical procedures and biologics suggests a growing demand in these areas, though the overall financial performance is still impacted by significant operating expenses and a history of losses.

Comparison to Industry Standards

• The company's revenue growth in medical procedures and biologics outpaces some smaller biotech firms, but its overall profitability and accumulated deficit are concerning compared to established players in the healthcare and supplement industries.
• The significant increase in revenue for medical procedures ($434,670 in H1 2026 vs. $96,700 in H1 2025) indicates strong market adoption for these specific treatments, potentially aligning with broader trends in personalized medicine and regenerative therapies.
• The company's reliance on a line of credit from its CEO ($835,312 outstanding) is a common, albeit risky, financing strategy for early-stage companies, but it highlights a dependence on related-party funding that differs from companies with diversified institutional backing.
• The explicit mention of 'substantial doubt about the ability of the Company to continue as a going concern' is a critical indicator that the company's financial health is below industry standards for established, stable businesses.

Legal Proceedings

• The company settled a lawsuit (Case Number: 2024CA001088) concerning the voiding of 15,495,165 shares of Common Stock and 10,000,000 shares of Series A Preferred Shares, with the settlement in favor of the Company on May 5, 2025.

Related Party Transactions

• The company has an unsecured line of credit facility with its Chief Executive Officer, which was increased to $1,000,000. As of June 30, 2026, the outstanding principal balance was $835,312.
• Interest expense on this line of credit was $22,766 for the six months ended June 30, 2026.
• Accrued interest on this line of credit was $60,681 as of June 30, 2026.
• The company leases office space from an entity controlled by the CEO and Director.

Stakeholder Impact

• Shareholders may be concerned about the company's ability to continue as a going concern, despite revenue growth.
• Creditors and lenders may face increased risk due to the company's net losses and accumulated deficit.
• Employees may face uncertainty regarding the company's long-term viability.
• Customers in the medical procedures and supplement segments may benefit from the company's focus on these areas, but their access to services/products could be impacted by financial instability.

Next Steps

• Continue to work with healthcare providers and health insurance companies to facilitate and provide AHSCT treatments for MS patients.
• Advocate for the inclusion and reimbursement of AHSCT treatments for MS patients by health insurance companies.
• Pursue strategic acquisitions and investments in the supplement industry.
• Continue to identify adequate sources of funding to provide bridge capital, financing of receivables, and operating capital.

Key Dates

Recommendation

The filing indicates substantial doubt about the company's ability to continue as a going concern, despite revenue growth. The significant accumulated deficit, ongoing net losses, and reliance on related-party financing present considerable financial risks that outweigh the positive revenue trends. A seasoned investor would likely view these factors as indicative of a high-risk investment, warranting a sell recommendation.

Keywords

Nutrition, Biologics, Medical Procedures, Healthcare, Supplements, Revenue, Loss, Going Concern